{"product_id":"evgn-vrio-analysis","title":"Evogene Ltd. (EVGN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the strategic DNA of Evogene Ltd. (EVGN) as we dissect its core competencies through the rigorous VRIO framework, testing its resources for true Value, Rarity, Inimitability, and Organization. This distilled summary cuts straight to the heart of its competitive standing, revealing precisely where its sustainable advantages lie - or where critical gaps threaten its market leadership. Engage with the analysis below to grasp the immediate implications of these findings.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 1. ChemPass AI Generative Engine\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re in the process of evaluating Evogene Ltd. (EVGN) after their major strategic pivot, and the core of that new direction is clearly the \u003cstrong\u003eChemPass AI\u003c\/strong\u003e engine. Honestly, this isn't just another piece of software; it’s the central asset they are betting the company on, especially after realizing about \u003cstrong\u003e$18.71 million\u003c\/strong\u003e from the ICL transaction involving other tech earlier in 2025. This engine, which powers their small molecule discovery for pharma and ag-chem, needs a hard look through the VRIO lens to see if it truly offers a lasting edge.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on what this engine means for their competitive standing, based on their Q3 2025 position where they held \u003cstrong\u003e$16.0 million\u003c\/strong\u003e in cash. The entire company is now streamlined around this technology, which is a big organizational shift following cost reductions and divestitures earlier in the year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eChemPass AI Generative Engine - VRIO Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eScore\/Implication\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2025 Data Context\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eDrives discovery and optimization of novel small molecules, significantly improving success rates and cutting time\/cost in R\u0026amp;D.\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eOperating loss for nine months of 2025 was \u003cstrong\u003e$8.8 million\u003c\/strong\u003e, showing the need for efficiency gains like those promised by AI.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eIts specific application and integration within their Computational Predictive Biology (CPB) platform make the proprietary algorithms quite unique.\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eThe engine is a core component of the CPB Platform, which leverages deep scientific understanding and big data.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eHigh. The AI models are built on years of proprietary data and iterative refinement, making direct imitation difficult and slow.\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eThe model is described as a first-in-class foundation model, developed in collaboration with Google Cloud.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh. Management has explicitly made this engine the core of the new, focused strategy, streamlining operations around it.\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eCEO stated the unified corporate focus is \u003cstrong\u003eChemPass AI\u003c\/strong\u003e following the strategic realignment.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained. This is the central, hard-to-replicate asset driving their future value proposition.\u003c\/td\u003e\n    \u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eThe company raised \u003cstrong\u003e$4.4 million\u003c\/strong\u003e in June 2025, reflecting market confidence in this focused strategy.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe technology itself is clearly valuable and rare, especially with the recent completion of its generative AI foundation model, version 1.0, in June 2025. What this estimate hides, though, is the actual time-to-market advantage it delivers versus competitors who might be using off-the-shelf AI tools. Still, the organizational commitment is defintely there; they sold off other assets to fund this focus.\u003c\/p\u003e\n\n\u003cp\u003eHere is a breakdown of the strategic implications:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue Driver:\u003c\/strong\u003e Focus on Pharma R\u0026amp;D, a higher-margin opportunity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk Mitigation:\u003c\/strong\u003e Reduces reliance on slower, traditional discovery methods.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIP Potential:\u003c\/strong\u003e Facilitates development of strong, defensible IP portfolios.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Alignment:\u003c\/strong\u003e Reduced operating expenses to \u003cstrong\u003e$7.7 million\u003c\/strong\u003e (nine months 2025) show cost discipline supporting the core tech.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 2. Computational Predictive Biology (CPB) Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe overarching system combines deep science with big data and AI to optimize product development across all their tech-engines. This platform is the result of over a decade long multidisciplinary effort, at an investment of \u003cstrong\u003etens of millions of dollars\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWhile AI platforms exist, Evogene's specific architecture integrating microbes, small molecules, and genetics is specialized. The CPB platform's core components for product development include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMicrobes\u003c\/li\u003e\n\u003cli\u003eSmall molecules\u003c\/li\u003e\n\u003cli\u003eGenetic elements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCompetitors can build AI, but replicating the specific scientific knowledge embedded in the CPB platform takes time. The platform's application spans multiple life-science segments, demonstrating breadth:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCore Component\u003c\/th\u003e\n\u003cth\u003eMarket Segment Use Case\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrobes\u003c\/td\u003e\n\u003ctd\u003eHuman Microbiome-based Therapeutics, Ag-Biologicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmall Molecules\u003c\/td\u003e\n\u003ctd\u003eDrug Discovery, Ag-Chemicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic Elements\u003c\/td\u003e\n\u003ctd\u003eSeed Traits, Medical Cannabis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe recent divestitures suggest a clearer focus on exploiting this platform's core strengths moving forward. As of September 30, 2025, Evogene held consolidated cash of \u003cstrong\u003e$16.0 million\u003c\/strong\u003e. Research and development expenses, net of non-refundable grants, for the first half of 2025 were approximately \u003cstrong\u003e$4.8 million\u003c\/strong\u003e, a decrease compared to \u003cstrong\u003e$6.5 million\u003c\/strong\u003e in the first half of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. It's strong now, but the pace of AI development means others could catch up if Evogene doesn't keep innovating the platform itself. Total R\u0026amp;D expenses for the 12 months of 2024 were approximately \u003cstrong\u003e$16.6 million\u003c\/strong\u003e, a decrease from approximately \u003cstrong\u003e$20.8 million\u003c\/strong\u003e in the 12 months of 2023.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 3. AgPlenus Integration and Ag-Chemical Focus\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides an established, revenue-generating channel (AgPlenus) to immediately apply ChemPass AI for next-generation crop protection products. Revenues for the 12 months of 2024 reached approximately $8.5 million, an increase from approximately $5.6 million in the year 2023, driven partly by AgPlenus\\'s collaboration with Bayer. AgPlenus utilizes Evogene\\'s ChemPass AI tech-engine for developing novel crop protection products.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having an operating ag-chemical subsidiary with existing development activity is rarer than just having the AI. AgPlenus had APH1, a broad weed-control spectrum herbicide candidate, as its most advanced product candidate in its pipeline as of the first quarter of 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can acquire or build ag-chem pipelines, but integrating it with Evogene's specific AI is the key barrier. The integration involves leveraging the ChemPass AI, which was enhanced by a generative AI foundation model trained on a proprietary dataset of approximately 38 billion molecular structures.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management specifically integrated AgPlenus deeper into core operations to maximize this synergy, including a 40% workforce reduction at AgPlenus in July 2025 as part of the optimization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The combination of a focused AI engine and an existing, relevant commercial arm creates a powerful, integrated offering.\u003c\/p\u003e\n\u003cp\u003eKey operational and financial data points related to the AgPlenus integration:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction at AgPlenus\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 2025, as part of integration into Evogene\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Total Revenues (Partially AgPlenus driven)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMost Advanced AgPlenus Candidate\u003c\/td\u003e\n\u003ctd\u003eAPH1 (Herbicide)\u003c\/td\u003e\n\u003ctd\u003eQ1 2023 pipeline status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Foundation Model Dataset Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38 Billion\u003c\/strong\u003e molecular structures\u003c\/td\u003e\n\u003ctd\u003eUsed to train the generative AI foundation model, applicable to ChemPass AI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe integration aims to unlock deeper synergies and operational efficiency by applying ChemPass AI to AgPlenus's development pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAgPlenus had a collaboration agreement with Corteva initiated in 2020.\u003c\/li\u003e\n\u003cli\u003eRevenues for the nine months ending September 30, 2025, were lower than the prior year, partially due to the absence of a one-time payment from Bayer recognized in the first quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 4. GeneRator AI Tech-Engine\n\u003c\/h2\u003e\n\u003cp\u003eGeneRator AI is one of Evogene's three core technology engines, specifically focused on the discovery and development of products based on genetic elements. This represents a distinct innovation pathway separate from the small molecule focus of ChemPass AI.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe engine's value is demonstrated through its application in Casterra Ag, which develops high-yield castor seed varieties for biofuel and other industries. Casterra delivered 250 tons of castor seeds to an African partner in Q1 2025, surpassing the 215 tons delivered in all of 2024.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eHaving a dedicated, developed engine for genetic elements is considered moderately rare compared to the more common general drug discovery AI platforms. Evogene maintains three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe technology represents a distinct, developed technological track requiring specific data sets and model training, suggesting a high degree of imitability difficulty.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe organizational commitment is currently moderate, as the company has strategically prioritized the ChemPass AI engine. This is evidenced by the recent sale of the MicroBoost AI for Ag engine to ICL for approximately $3.5 million.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe competitive impact is currently secondary to the ChemPass AI focus, positioning the advantage as temporary, despite the engine being a valuable resource.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAI Tech-Engine\u003c\/th\u003e\n\u003cth\u003ePrimary Focus\u003c\/th\u003e\n\u003cth\u003eRelated Subsidiary\/Asset\u003c\/th\u003e\n\u003cth\u003eRecent Financial\/Operational Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneRator AI\u003c\/td\u003e\n\u003ctd\u003eGenetic Elements\u003c\/td\u003e\n\u003ctd\u003eCasterra Ag\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e250 tons\u003c\/strong\u003e of castor seeds delivered in Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicroBoost AI\u003c\/td\u003e\n\u003ctd\u003eMicrobes\u003c\/td\u003e\n\u003ctd\u003eLavie Bio (Divested)\u003c\/td\u003e\n\u003ctd\u003eSale of MicroBoost AI for Ag for approximately \u003cstrong\u003e$3.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemPass AI\u003c\/td\u003e\n\u003ctd\u003eSmall Molecules\u003c\/td\u003e\n\u003ctd\u003eAgPlenus, Pharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eTrained on \u003cstrong\u003e38 billion\u003c\/strong\u003e molecules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic realignment is reflected in the following financial figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for Q1 2025 were approximately \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, a decrease from approximately \u003cstrong\u003e$4.8 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003cli\u003eTotal operating expenses for Q3 2025 were reduced to approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e, down from \u003cstrong\u003e$6.6 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe agreement to sell most of Lavie Bio and the MicroBoost AI for Ag platform is expected to inject approximately \u003cstrong\u003e$18.75 million\u003c\/strong\u003e into Evogene's cash position.\u003c\/li\u003e\n\u003cli\u003eCasterra's seed sales in Q1 2025 surpassed the total delivered in 2024 by \u003cstrong\u003e15 tons\u003c\/strong\u003e (\u003cstrong\u003e250 tons\u003c\/strong\u003e vs. \u003cstrong\u003e215 tons\u003c\/strong\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 5. Casterra Subsidiary and Castor Seed Assets\n\u003c\/h2\u003e\n\u003cp\u003eCasterra Ag Ltd. operates as the industrial applications segment for Evogene, focusing on developing improved castor bean seeds for industrial uses, including feedstock for biofuels.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Generates direct revenue from seed sales and offers a unique, non-AI-core business line that provides diversification and potential value realization. Casterra's revenue contribution is evident in the consolidated figures, with total revenues for the year 2024 reaching approximately \u003cstrong\u003e$8.5 million\u003c\/strong\u003e, an increase from approximately \u003cstrong\u003e$5.6 million\u003c\/strong\u003e in 2023, an increase partly attributed to Casterra's seed sales. In the first half of 2025, total revenues amounted to approximately \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$2.3 million\u003c\/strong\u003e in the first half of 2024, primarily driven by higher seed sales generated by Casterra. Sales and Marketing expenses for the first half of 2024 were approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e, showing an increase attributable to increased sales and marketing activities in Casterra.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Owning industrial-scale castor seed IP and sales channels is a tangible, non-computational asset. Casterra secured initial purchase orders in 2023 totaling \u003cstrong\u003e$11.3 million\u003c\/strong\u003e for its proprietary castor plant seeds. An additional purchase order valued at approximately \u003cstrong\u003e$440K\u003c\/strong\u003e was announced on June 25, 2024. As of June 25, 2024, the remaining revenue from unsupplied orders was approximately \u003cstrong\u003e$8.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Replicating superior castor seed varieties and the associated commercialization know-how is a biological\/agricultural challenge. Casterra's seeds are developed utilizing Evogene's GeneRator AI tech-engine. In Q4 2024, Casterra delivered approximately \u003cstrong\u003e76 tons\u003c\/strong\u003e of castor seeds, while in February 2025 alone, the company delivered approximately \u003cstrong\u003e250 tons\u003c\/strong\u003e of castor seeds.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. Management intends to focus on generating value through its holdings here, signaling active management, not abandonment. As of June 30, 2024, Evogene's consolidated cash of approximately \u003cstrong\u003e$20.9 million\u003c\/strong\u003e did not include \u003cstrong\u003e$8.4 million\u003c\/strong\u003e of expected payments for Casterra's open purchase orders. Sales and Marketing expenses for the first half of 2024 were approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e, a slight increase from approximately \u003cstrong\u003e$1.7 million\u003c\/strong\u003e in the same period in the previous year, with the increase mainly attributable to increased sales and marketing activities in Casterra.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a good asset, but it doesn't directly benefit from the company's primary AI strategy. The global biodiesel market size was estimated at \u003cstrong\u003e$36.48 billion\u003c\/strong\u003e in 2022 and is expected to reach around \u003cstrong\u003e$79.12 billion\u003c\/strong\u003e by 2032. The global Castor Oil Market reached \u003cstrong\u003eUS$ 1.23 billion\u003c\/strong\u003e in 2022 and is expected to reach \u003cstrong\u003eUS$ 1.98 billion\u003c\/strong\u003e by 2030.\u003c\/p\u003e\n\n\u003cp\u003eFinancial Performance Metrics Related to Casterra:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Year\/Period)\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$8.5 million\u003c\/strong\u003e (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eIncrease from \u003cstrong\u003e$5.6 million\u003c\/strong\u003e in FY 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.6 million\u003c\/strong\u003e (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003eIncrease from \u003cstrong\u003e$0.6 million\u003c\/strong\u003e in Q4 2023, mainly due to Casterra's seed sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH1 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.2 million\u003c\/strong\u003e (H1 2025)\u003c\/td\u003e\n\u003ctd\u003eIncrease from \u003cstrong\u003e$2.3 million\u003c\/strong\u003e in H1 2024, driven by Casterra seed sales.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 Purchase Orders Total\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.3 million\u003c\/strong\u003e (2023)\u003c\/td\u003e\n\u003ctd\u003eInitial orders included \u003cstrong\u003e$9.1 million\u003c\/strong\u003e and \u003cstrong\u003e$2.2 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 2024 Purchase Order\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~$440K\u003c\/strong\u003e (June 2024)\u003c\/td\u003e\n\u003ctd\u003eAdditional order from an existing customer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnsupplied Order Revenue (as of June 2024)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$8.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpected to be recognized in H2 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCastor Seed Delivery\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e250 tons\u003c\/strong\u003e (Feb 2025)\u003c\/td\u003e\n\u003ctd\u003eCompared to approximately \u003cstrong\u003e76 tons\u003c\/strong\u003e delivered in Q4 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCasterra's operational and commercial milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCasterra announced receiving a \u003cstrong\u003e$440K\u003c\/strong\u003e purchase order on June 25, 2024, to supply castor seeds to a new African country in 2024.\u003c\/li\u003e\n\u003cli\u003eThe company's initial 2023 purchase orders totaled \u003cstrong\u003e$11.3 million\u003c\/strong\u003e for supply during 2023 for biofuel production in Africa.\u003c\/li\u003e\n\u003cli\u003eCasterra operates an R\u0026amp;D center in Israel and a local production site in Brazil, with another site in Zambia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 6. Post-Realignment Cost Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Significantly reduced operating expenses, with Q3 2025 operating expenses at approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e compared to approximately \u003cstrong\u003e$6.6 million\u003c\/strong\u003e in Q3 2024, extending runway. As of the end of the third quarter of 2025, the company's cash and short-term bank deposits balance was approximately \u003cstrong\u003e$16.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric (in thousands USD)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2025\u003c\/td\u003e\n\u003ctd\u003eNine Months Ended Sept 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses, net\u003c\/td\u003e\n\u003ctd\u003e2,879\u003c\/td\u003e\n\u003ctd\u003e6,618\u003c\/td\u003e\n\u003ctd\u003e10,551\u003c\/td\u003e\n\u003ctd\u003e17,670\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e(2,724)\u003c\/td\u003e\n\u003ctd\u003e(5,920)\u003c\/td\u003e\n\u003ctd\u003e(8,822)\u003c\/td\u003e\n\u003ctd\u003e(15,324)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe new expense level of approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e for Q3 2025 is expected to be maintained going forward.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Cost-cutting is common, but the completion of a major plan is a specific, timely achievement. The organizational change and cost reduction initiative was executed as part of the strategic transition.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can cut costs, but this is a result of Evogene's specific past restructuring decisions. The organizational realignment and cost-reduction plan was most of which was completed by the end of the \u003cstrong\u003esecond quarter of 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The organizational realignment was decisive and completed by \u003cstrong\u003eQ2 2025\u003c\/strong\u003e, showing management's ability to execute tough changes. This is further evidenced by the reduction in operating loss for the nine months of 2025 to approximately \u003cstrong\u003e$8.8 million\u003c\/strong\u003e compared to approximately \u003cstrong\u003e$15.3 million\u003c\/strong\u003e in the same period of 2024.\u003c\/p\u003e\n\u003cp\u003eDetailed expense components contributing to the cost structure change include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGeneral and administrative expenses for Q3 2025 decreased to approximately \u003cstrong\u003e$1.1 million\u003c\/strong\u003e compared to approximately \u003cstrong\u003e$2.8 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses, net of non-refundable grants, for the nine months of 2025 were approximately \u003cstrong\u003e$6.2 million\u003c\/strong\u003e, a decrease of approximately \u003cstrong\u003e$3.6 million\u003c\/strong\u003e compared to \u003cstrong\u003e$9.8 million\u003c\/strong\u003e in the nine months of 2024.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses in Q3 2025 were approximately \u003cstrong\u003e$1.4 million\u003c\/strong\u003e, down from approximately \u003cstrong\u003e$3.3 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSales and marketing expenses for the nine months of 2025 totaled approximately \u003cstrong\u003e$1.1 million\u003c\/strong\u003e, compared to approximately \u003cstrong\u003e$1.6 million\u003c\/strong\u003e in the same period of 2024.\u003c\/li\u003e\n\u003cli\u003eSales and marketing expenses for Q3 2025 were approximately \u003cstrong\u003e$0.4 million\u003c\/strong\u003e, reflecting a slight decrease of approximately \u003cstrong\u003e$0.1 million\u003c\/strong\u003e compared to approximately \u003cstrong\u003e$0.5 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This efficiency improves the current financial picture but is not a source of long-term revenue or IP advantage. The operating loss for Q3 2025 was approximately \u003cstrong\u003e$2.7 million\u003c\/strong\u003e, a decrease from approximately \u003cstrong\u003e$5.9 million\u003c\/strong\u003e in Q3 2024, primarily due to decreased operating expenses.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 7. Financial Liquidity Post-Divestiture\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A cash balance of approximately \u003cstrong\u003e$16.0 million\u003c\/strong\u003e as of September 30, 2025, provides a solid buffer following the sale of Lavie Bio and MicroBoost AI for Ag assets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The cash position is bolstered by specific, non-recurring asset sales, making the current level unique to this point in time. The transaction involved the sale of the majority of Lavie Bio's activity for an aggregate consideration of US$\u003cstrong\u003e15.25 million\u003c\/strong\u003e and the MicroBoost AI tech-engine for approximately $\u003cstrong\u003e3.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can raise capital, but this specific cash pile is a direct result of Evogene's recent transactions. The sale generated income, net, of approximately $\u003cstrong\u003e7.9 million\u003c\/strong\u003e in the third quarter of 2025 alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company successfully monetized non-core assets to fund its focused strategy. The cash balance as of September 30, 2025, reflects the proceeds from this sale.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Cash is fungible; the advantage lies in how they deploy it to advance ChemPass AI. The company's operational cash usage provides context for this liquidity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsolidated cash usage during the third quarter of 2025, excluding the cash generated from the sale, was approximately $\u003cstrong\u003e3.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash usage excluding Lavie Bio and Biomica for Q3 2025 was approximately $\u003cstrong\u003e2.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe financial position as of September 30, 2025, compared to prior periods highlights the impact of the divestiture:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Millions USD)\u003c\/th\u003e\n\u003cth\u003eAs of Sep 30, 2025\u003c\/th\u003e\n\u003cth\u003eAs of Jun 30, 2025\u003c\/th\u003e\n\u003cth\u003eAs of Jun 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, cash equivalents and short-term bank deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Growth (vs. prior period)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e-44.08% (vs. Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 8. Expertise in Microbiome Therapeutics (Biomica)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Retained scientific knowledge and development capability in microbiome-based therapeutics, powered by the MicroBoost AI engine, despite scaling down operations. Evidence includes the BMC128 Phase I study showing early signs of immune activation within \u003cstrong\u003e14 days\u003c\/strong\u003e of monotherapy. The underlying computational platform, PRISM, is powered by Evogene's MicroBoost AI tech-engine.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Deep expertise in microbiome R\u0026amp;D, even if streamlined, is a specialized asset in the life sciences. Biomica is a clinical-stage company focused on this area.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building a team with this specific therapeutic focus and underlying AI knowledge, such as the PRISM platform, is a multi-year effort.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. While operations were scaled down, the underlying IP and scientific team structure likely remain a resource. The subsidiary previously secured a financing round of \u003cstrong\u003e$20 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Its competitive impact is muted until Biomica's activities are re-prioritized or monetized, reflected in reduced R\u0026amp;D expenses for the nine months of 2025 being approximately \u003cstrong\u003e$6.2 million\u003c\/strong\u003e, down from $9.8 million in the same period of 2024, largely due to reduced Biomica R\u0026amp;D activity.\u003c\/p\u003e\n\u003cp\u003eKey Operational and Financial Data Points:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMC128 Phase I Enrollment Completion\u003c\/td\u003e\n\u003ctd\u003eJanuary 17, 2024\u003c\/td\u003e\n\u003ctd\u003eCompletion of enrollment for the Phase I trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMC128 Trial Participants (Preliminary Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of patients in the Phase I combination study for which preliminary data was presented\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMC128 Efficacy Signal\u003c\/td\u003e\n\u003ctd\u003eWithin \u003cstrong\u003e14 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTimeframe for observing early signs of monotherapy effectiveness via immune activation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomica Prior Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount raised in a financing round led by Shanghai Healthcare Capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense Reduction (9M 2025 vs 9M 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.6 million\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003ctd\u003eDecrease in R\u0026amp;D expenses attributed partly to reduced Biomica R\u0026amp;D activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Operating Expenses, Net\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompared to approximately $6.6 million in Q3 2024, reflecting scaled-down activity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eUnderlying Technological Assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMicrobiome-based therapeutics development utilizing Evogene's \u003cstrong\u003eMicroBoost AI\u003c\/strong\u003e tech-engine.\u003c\/li\u003e\n\u003cli\u003eDrug candidates identified and designed using the \u003cstrong\u003ePRISM\u003c\/strong\u003e proprietary computational platform.\u003c\/li\u003e\n\u003cli\u003ePipeline includes BMC128 (Immuno-oncology) and BMC333 (Inflammatory Bowel Disease - IBD).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvogene Ltd. (EVGN) - VRIO Analysis: 9. Exclusive Licensing and Collaboration Framework\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Q4 2025 Cash Burn Projection (Based on Q3 Operating Expenses)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe consolidated cash usage for Evogene and its other subsidiaries, excluding Lavie Bio and Biomica, during the third quarter of 2025 was approximately \u003cstrong\u003e$2.3 million\u003c\/strong\u003e. Based on this core operational cash usage rate, the projected Q4 2025 cash burn is \u003cstrong\u003e$2.3 million\u003c\/strong\u003e, assuming a maintained expense level going forward.\u003c\/p\u003e\n\n\u003ch3\u003eValue: The established model of using tech-engines to develop products via exclusive licenses and strategic partnerships allows for non-dilutive value capture.\u003c\/h3\u003e\n\u003cp\u003eThe framework captures value through licensing Evogene's AI Tech-Engines to third parties, including its subsidiaries, for product development. The company utilizes three unique tech-engines: MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTech Engine\u003c\/th\u003e\n\u003cth\u003eCore Component\u003c\/th\u003e\n\u003cth\u003ePrimary Business Model Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemPass AI\u003c\/td\u003e\n\u003ctd\u003eSmall Molecules\u003c\/td\u003e\n\u003ctd\u003eLicensing \u0026amp; Joint Product Development (Pharma\/Ag)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicroBoost AI\u003c\/td\u003e\n\u003ctd\u003eMicrobes\u003c\/td\u003e\n\u003ctd\u003eSubsidiary Development (Biomica) \u0026amp; Past Asset Sale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneRator AI\u003c\/td\u003e\n\u003ctd\u003eGenetic Elements\u003c\/td\u003e\n\u003ctd\u003eSubsidiary Development (Casterra, Finally Foods)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: Moderate. Many firms do this, but Evogene's framework is tailored to their specific AI output (molecules, microbes, genes).\u003c\/h3\u003e\n\u003cp\u003eThe framework is tailored to commercialize outputs from distinct, proprietary AI platforms focused on specific biological components. The company has established collaborations with leading life-science companies. The sale of the MicroBoost AI for Ag tech-engine to ICL for a total of \u003cstrong\u003e$18.71 million\u003c\/strong\u003e in July 2025 demonstrates a realized value event for one of these specific outputs.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Moderate. The legal and operational framework for these deals is established, reducing friction for new partners.\u003c\/h3\u003e\n\u003cp\u003eThe established structure for value capture includes defined revenue streams from collaborations and licensing. The legal and operational framework is designed to reduce friction for new partners. The company recorded a gain on sale of approximately \u003cstrong\u003e$6.4 million\u003c\/strong\u003e in Q3 2025 related to the sale of Lavie Bio's assets and MicroBoost AI for Ag.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLicense fees \u0026amp; R\u0026amp;D reimbursement.\u003c\/li\u003e\n\u003cli\u003eDividends to Evogene as a shareholder.\u003c\/li\u003e\n\u003cli\u003eSignificant one-time-payment upon an exit event.\u003c\/li\u003e\n\u003cli\u003eUpfront payments, R\u0026amp;D fees, Milestone payments, Royalties from sale of end-products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization: High. This framework is how they translate their R\u0026amp;D into realized income, as seen with past deals.\u003c\/h3\u003e\n\u003cp\u003eThe framework is the mechanism for translating R\u0026amp;D from the ChemPass AI tech engine and others into realized income. As of September 30, 2025, Evogene held consolidated cash, cash equivalents, and short-term bank deposits of approximately \u003cstrong\u003e$16.0 million\u003c\/strong\u003e. The operating loss for the third quarter of 2025 was approximately \u003cstrong\u003e$2.7 million\u003c\/strong\u003e, a decrease from approximately \u003cstrong\u003e$5.9 million\u003c\/strong\u003e in Q3 2024, reflecting streamlined operations.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained. A proven, repeatable mechanism for external value extraction is a key operational strength.\u003c\/h3\u003e\n\u003cp\u003eThe repeatable mechanism for external value extraction, involving both subsidiaries and external partners like Bayer and Corteva (historical validation), provides a sustained operational strength. The company's total operating expenses, net, for Q3 2025 were approximately \u003cstrong\u003e$2.9 million\u003c\/strong\u003e, down from approximately \u003cstrong\u003e$6.6 million\u003c\/strong\u003e in Q3 2024, showing cost discipline supporting the framework's efficiency.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516160827541,"sku":"evgn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/evgn-vrio-analysis.png?v=1740172028","url":"https:\/\/dcf-model.com\/fr\/products\/evgn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}